Preclinical studies have shown that paclitaxel can activate antitumor immunity by inducing immunogenic cell death, which increases PD-L1 expression within the tumor microenvironment, stimulates natural killer cells and T lymphocytes, and affects macrophage polarization, thereby enhancing PD-1 antibody efficacy (13–21). The gene discussed is PDCD1; the disease is neoplasm.